Table 5 Comparison of CD 34 yields of the study population and historical controls.

From: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial

Variable

1st apheresis median (IQR) MOBIL-1

2nd apheresis median (IQR) MOBIL-1

1st apheresis median (IQR) historical controls

2nd apheresis median (IQR) historical controls

CD34 + [×108]

1.05 (0.64–1.41)

2.80 (2.32–3.71)

1.27 (1–1.5)

0.9 (0.65–1.29)

CD34 + [×106/kg RBW]

1.31 (0.8–1.65)

3.74 (2.26–4.69)

1.63 (1.32–1.84)

1.15 (0.8–1.57)

Total amount of CD34 + cells [x106/kg RBW]

5.16 (3.06–6.10)

2.77 (2.28–3.27)

Donors reaching target

>4.5 ×106/kg

21/37 (57%, 95%CI 40–73%)

11/168 (7%, 95%CI 6–16%)

Donors reaching target

>4.0 × 106/kg

23/37 (62%, 95%CI 45–78%)

18/168 (11%, 95%CI 3–11%)

  1. Data on 168 healthy allogeneic donors who donated <2 × 106 /kg in 1st apheresis at the trial sites before 2012.
  2. IQR inter quartile range, RBW recipient body weight, CI confidence interval.
Back to article page